Two New York-area specialty firms saw their disparate strategies come together in a single deal announced Nov. 29 as Melinta Therapeutics Inc. agreed to acquire The Medicines Co.’s three-product antibiotic franchise and commercial team for roughly $270m plus earn-outs.
The transaction enables TMC to make good on a strategy announced weeks ago to downsize significantly and focus on Phase...








